Top 10 Companies in the Global 4‑Phenylbutyric Acid Market (2026): Market Leaders Powering Global Pharmaceutical Innovation

MARKET INSIGHTS

Global 4‑Phenylbutyric Acid market size was valued at USD 245.7 million in 2024. The market is projected to grow from USD 265.9 million in 2025 to USD 389.4 million by 2032, exhibiting a CAGR of 5.8% during the forecast period.

4‑Phenylbutyric Acid (4‑PBA) is a small molecular compound with both phenyl and carboxylic acid functional groups, primarily used as a pharmaceutical intermediate and chemical chaperone. This organic compound plays a critical role in protein folding regulation and has applications in treating urea cycle disorders like Hyperammonemia. The product is available in varying purity grades (98% and 99%) to meet different industrial requirements.

The market growth is being driven by increasing pharmaceutical applications, particularly in rare disease treatments, and rising demand from the biotechnology sector. While North America currently dominates consumption due to advanced healthcare infrastructure, Asia‑Pacific is emerging as the fastest‑growing region because of expanding pharmaceutical manufacturing capabilities. Key manufacturers like Zhejiang Shaxing Technology and Seqens are investing in capacity expansion to meet the growing global demand.

Global 4‑Phenylbutyric Acid Market – View in Detailed Research Report

---

Top 10 Companies in the Global 4‑Phenylbutyric Acid Market (2026)

1. Zhejiang Shaxing Technology (China)

Headquarters: Zhejiang, China
Key Offering: High‑purity 4‑PBA (98% & 99%) for pharmaceutical intermediates and research applications

Zhejiang Shaxing Technology has established itself as a leading fine‑chemical manufacturer with state‑of‑the‑art synthesis facilities. The company focuses on producing GMP‑grade 4‑PBA to support drug discovery and development for metabolic and neurodegenerative disorders.

Sustainability & Growth Initiatives: Investment in green chemistry processes, waste‑reduction technologies, and renewable energy sourcing for production.

• Capacity expansion of 30% by 2026 to meet global demand.
• Partnerships with major pharmaceutical firms for joint R&D.
• Implementation of ISO 14001 and ISO 9001 certification.

2. Seqens (France)

Headquarters: Paris, France
Key Offering: 4‑PBA for chemical chaperone research and therapeutic development

Seqens specializes in high‑quality fine chemicals for the pharmaceutical and biotechnology sectors. Its 4‑PBA portfolio is widely used in preclinical and clinical studies targeting protein misfolding diseases.

Sustainability & Growth Initiatives: Adoption of advanced catalytic processes to reduce carbon footprint and support circular economy principles.

• Launch of a 4‑PBA supply contract with a leading U.S. biotech company.
• Investment in process automation for cost efficiency.
• Research collaboration with European universities.

3. Tokyo Chemical Industry Co., Ltd. (Japan)

Headquarters: Tokyo, Japan
Key Offering: 4‑PBA (98% & 99%) for industrial and research applications

TCI is a global chemical supplier known for its high‑purity specialty chemicals. Its 4‑PBA is used in drug formulation, analytical chemistry, and advanced materials research.

Sustainability & Growth Initiatives: Implementation of energy‑efficient manufacturing lines and reduction of hazardous waste.

• Expansion of production capacity by 20% in 2026.
• Strategic alliance with a leading Korean pharmaceutical company.
• Investment in biodegradable solvent technologies.

4. Santa Cruz Biotechnology, Inc. (USA)

Headquarters: Santa Cruz, California, USA
Key Offering: 4‑PBA for research reagents and therapeutic development

Santa Cruz Biotechnology provides high‑quality research chemicals. Its 4‑PBA is a staple reagent for studies on ER stress and protein folding.

Sustainability & Growth Initiatives: Commitment to green laboratory practices and sustainable packaging.

• Partnership with a major U.S. university for joint research.
• Launch of a new 4‑PBA line with 99.5% purity.
• Implementation of a waste‑reduction program.

5. Cayman Chemical Company (USA)

Headquarters: Ann Arbor, Michigan, USA
Key Offering: 4‑PBA for pharmaceutical and research applications

Cayman Chemical is a leading supplier of research chemicals and custom synthesis. Its 4‑PBA is used in drug discovery and analytical testing.

Sustainability & Growth Initiatives: Focus on reducing solvent usage and promoting renewable energy in facilities.

• Expansion of custom synthesis capabilities.
• Collaboration with a European biotech firm.
• Implementation of a digital tracking system for batch traceability.

6. Merck KGaA (Germany)

Headquarters: Darmstadt, Germany
Key Offering: 4‑PBA for pharmaceutical intermediates and specialty chemicals

Merck KGaA is a global leader in pharmaceuticals and chemicals. Its 4‑PBA is utilized in the synthesis of therapeutic agents and as a chemical chaperone.

Sustainability & Growth Initiatives: Commitment to circular economy and reduction of CO2 emissions across the supply chain.

• Launch of a 4‑PBA supply agreement with a major U.S. pharma company.
• Investment in renewable energy for manufacturing plants.
• Research collaboration on novel drug delivery systems.

7. Shanghai Acmec Biochemical Co., Ltd. (China)

Headquarters: Shanghai, China
Key Offering: 4‑PBA for pharmaceutical and industrial applications

Shanghai Acmec Biochemical specializes in fine chemicals for the pharmaceutical industry. Its 4‑PBA supports drug development for rare diseases.

Sustainability & Growth Initiatives: Adoption of green synthesis routes and waste minimization strategies.

• Expansion of production capacity by 25% in 2026.
• Partnership with a leading Chinese university.
• Implementation of ISO 14001 certification.

8. Alfa Aesar (Thermo Fisher Scientific) (USA)

Headquarters: Houston, Texas, USA
Key Offering: 4‑PBA for research and industrial use

Alfa Aesar, a Thermo Fisher brand, supplies high‑purity chemicals for scientific research and industrial processes. Its 4‑PBA is widely used in laboratories worldwide.

Sustainability & Growth Initiatives: Focus on sustainable sourcing and reducing single‑use plastics.

• Launch of a new 4‑PBA product line with 99.9% purity.
• Collaboration with a major European research institute.
• Implementation of a digital inventory management system.

9. Bayer AG (Germany)

Headquarters: Leverkusen, Germany
Key Offering: 4‑PBA for pharmaceutical intermediates and biopharmaceutical development

Bayer AG is a global pharmaceutical and life‑sciences company. Its 4‑PBA is used in the synthesis of novel therapeutic agents.

Sustainability & Growth Initiatives: Commitment to sustainability in manufacturing and reduction of water usage.

• Strategic partnership with a U.S. biotech firm for joint R&D.
• Investment in renewable energy for production facilities.
• Launch of a sustainability reporting framework.

10. Wako Pure Chemical Industries (Japan)

Headquarters: Osaka, Japan
Key Offering: 4‑PBA for research, analytical, and pharmaceutical applications

Wako Pure Chemical Industries provides high‑quality chemicals for research and industry. Its 4‑PBA supports drug discovery and quality control testing.

Sustainability & Growth Initiatives: Implementation of eco‑friendly production processes and waste recycling.

• Expansion of production capacity by 15% in 2026.
• Collaboration with a leading Japanese university.
• Implementation of a digital quality management system.

---

Download FREE Sample Report: Global 4‑Phenylbutyric Acid Market

Get Full Report: Global 4‑Phenylbutyric Acid Market

---

Outlook

Looking ahead, the global 4‑Phenylbutyric Acid market is expected to maintain a steady growth trajectory through 2034, driven by expanding therapeutic applications in protein‑folding disorders and the increasing demand from the biotechnology sector. Market analysts project a CAGR of 5.8% from 2026 to 2034, with the Asia‑Pacific region capturing the largest share due to its robust manufacturing base and growing pharmaceutical pipeline.

Future Trends

Key future trends include the development of sustained‑release formulations of 4‑PBA, integration of 4‑PBA in combination therapies for neurodegenerative diseases, and the adoption of advanced manufacturing technologies such as continuous flow synthesis to enhance purity and reduce costs. Additionally, regulatory support for orphan drug designations is expected to accelerate market penetration in rare disease indications, while emerging markets in Latin America and the Middle East are poised to contribute to regional growth.